This website is intended for healthcare professionals only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

Female breast anatomy glowing orange, 3d Medical illustration, women's health

Clinically Challenging Tuberculous Mastitis from an Endemic Area: A Retrospective Case Series

Aqsa Jawaid Siddiqui, Aamir Sikandar Kazi, Ghina Shamim Shamsi

Tuberculous mastitis (TM) is a rare chronic granulomatous disease predominantly caused by Mycobacterium tuberculosis.1 TM accounts for less than 0.1% of all breast diseases worldwide, whereas it is more common in endemic regions (3–4.5%).2,3 TM is more prevalent in the reproductive age group, especially during the lactation period, when patients are more susceptible since the […]

touchREVIEWS in Infectious Diseases. 2026;5(1):Online ahead of journal publication

HIV

Amesika Nyaku, ACTHIV 2022: Future directions in HIV research

Published Online: May 30th 2022

There are number of new and emerging therapies for the treatment of HIV. Dr Amesika Nyaku (Rutgers New Jersey Medical School, Newark, NJ, USA) joins touchINFECTIOUS DISEASES to discuss the future directions HIV treatment research.

View more content from Dr Amesika Nyaku:

The presentation entitled: ‘New Antiretroviral Agents and When to Use Them’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.

Questions:

What are the future directions in HIV treatment research? (0:14)

Disclosures: Amesika Nyaku has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ACTHIV 2022

RIO phase II study reveals promise for broadly neutralising antibodies in achieving HIV remission without daily antiretroviral therapy

The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.

Related Videos in HIV

Developed by Touch

A new chapter in HIV research: Dr Sarah Fidler on the promise of harnessing immunity with broadly neutralising antibodies

Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

HIV vaccine advances: insights from CROI 2024

Barney Graham

HIV vaccine development harnesses breakthroughs in structure-based antigen design, sequencing, and single-cell analysis to create potent vaccines. Prof. Barney Graham, Professor of Medicine, Microbiology, Chemistry and Immunology, Morehouse School of Medicine in Atlanta, Georgia, USA explores advances reported at CROI 2024, emphasizing advances in targeting antibody lineages and augmenting CD8+ T cell responses, and highlighting sustaining funding models for HIV research and it's imperativeness for addressing broader public health issues.

Developed by Touch

Pioneering HIV vaccine research through regional advances and vaccine equity

Barney Graham

HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.

Developed by Touch

Evolving HIV diagnostic technologies: A new era of precision

Nitika Pai

HIV diagnostic technologies are rapidly advancing, as Dr. Nitika Pai discussed, with self-tests and multiplex testing leading the way in accuracy and accessibility. The challenge remains in cost and strategic deployment. This field interests infectious disease specialists, clinical epidemiologists, and public health professionals. Stay informed on innovations like CRISPR and machine learning to enhance patient care. NAT (Nucleic Acid Test) costs and algorithmic bias in machine learning need attention for equitable access.

Developed by Touch

HIV diagnostic innovations: revolutionizing the fight against HIV

Nitika Pai

HIV diagnostics have transformed post-COVID, enhancing the acceptance and implementation of self-tests globally. Dr Nitika Pai, Division of Clinical Epidemiology, Experimental Medicine, Infectious Disease, McGill University, Montreal, Canada, discusses advancements in HIV diagnostics, especially self-testing, which has increased the acceptance and implementation of HIV self-tests globally.

Developed by Touch

Antiretroviral management of HIV in clinical practice: integration of the latest data

Eric Daar

Learn about the integration of the latest data in antiretroviral management of HIV, challenges clinicians may face when adopting new strategies and updates from the Conference of Retroviruses and Opportunistic Infections (CROI) 2024 are reported here by Dr Eric Daar, Division of HIV Medicine, Harbor-UCLA Medical Center, Atlanta, GA, USA.

Developed by Touch

Antiretroviral therapy updates at CROI 2024: emerging treatment strategies in HIV

Eric Daar

Antiretroviral therapy (ART) effectively manages HIV by suppressing viral replication. It's crucial for healthcare professionals (HCPs) to keep abreast of ART updates for optimal patient care. Dr. Eric Daar, Harbor-UCLA Medical Center, reports on CROI 2024, underscoring the efficacy of long-acting injectable (LAI) therapies in trials like CARES, MOCHA, and LATITUDE. The findings support LAI therapy's potential for global HIV treatment programs, including in resource-limited settings like sub-Saharan Africa.

Developed by Touch

Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023

Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and ...

Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen

Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of ...

Developed by Touch

HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen

Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for ...

Developed by Touch

Patient Perspective, Yvette Raphael: Inclusivity of women and underrepresented populations in HIV clinical trials

It was a pleasure to meet with Yvette Raphael, patient advocate in HIV and Executive Director of Advocacy for Prevention of HIV and AIDS (APHA), South Africa, to share her perspective on the barriers of women and other populations being ...

Developed by Touch

Patient perspective, Yvette Raphael: Landscape of HIV treatment and prevention in women and at-risk populations

It was a pleasure to meet with Yvette Raphael, patient advocate in HIV and Executive Director of Advocacy for Prevention of HIV and AIDS (APHA), South Africa, to share her perspective on evolving research, especially the use of bNAbs for ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Clinically Challenging Tuberculous Mastitis from an Endemic Area: A Retrospective Case Series

Learning Activities

Congress Highlights

Journals

Specialities

Clinically Challenging Tuberculous Mastitis from an Endemic Area: A Retrospective Case Series

Amesika Nyaku, ACTHIV 2022: Future directions in HIV research

Register now for
FREE access

RIO phase II study reveals promise for broadly neutralising antibodies in achieving HIV remission without daily antiretroviral therapy

A new chapter in HIV research: Dr Sarah Fidler on the promise of harnessing immunity with broadly neutralising antibodies

HIV vaccine advances: insights from CROI 2024

Pioneering HIV vaccine research through regional advances and vaccine equity

Evolving HIV diagnostic technologies: A new era of precision

HIV diagnostic innovations: revolutionizing the fight against HIV

Antiretroviral management of HIV in clinical practice: integration of the latest data

Antiretroviral therapy updates at CROI 2024: emerging treatment strategies in HIV

Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023

Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen

HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen

Patient Perspective, Yvette Raphael: Inclusivity of women and underrepresented populations in HIV clinical trials

Patient perspective, Yvette Raphael: Landscape of HIV treatment and prevention in women and at-risk populations

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Congress Highlights

Trending Topic

Connect With Us:

Amesika Nyaku, ACTHIV 2022: Future directions in HIV research

Register now forFREE access

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

Register now for FREE access

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Register now for
FREE access